Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zelesudil
- Development stage
- Unknown
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
Zelesudil (formerly AR-13503) is a small molecule dual inhibitor of Rho-associated protein kinase (ROCK) and protein kinase C (PKC). Developed by Aerie Pharmaceuticals (now a subsidiary of Alcon), it is specifically designed for the treatment of retinal diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The drug's mechanism involves the simultaneous inhibition of ROCK and PKC pathways, which are implicated in vascular leakage, inflammation, and fibrosis within the eye. Zelesudil is typically administered as an intravitreal injection, often utilizing a sustained-release (SR) implant technology to maintain therapeutic levels over several months, potentially reducing the treatment burden for patients with chronic retinal conditions.
- Other names
- zelesudilAR-13503AR13503AR 13503
02
Targets
PRKCI (Protein kinase C iota)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on zelesudil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zelesudil.